Metformin Management with CT Contrast: Evidence-Based Guidelines

Renal Function-Based Decision Algorithm

• The American Diabetes Association recommends continuing metformin without interruption for contrast-enhanced CT procedures in patients with eGFR ≥60 mL/min/1.73 m² 1, 2
• The European Journal of Nuclear Medicine and Molecular Imaging suggests stopping metformin at the time of or prior to the iodinated contrast procedure in patients with moderate renal impairment (eGFR 30-60 mL/min/1.73 m²) 1, 2

Dosing and Contraindications

• The Kidney International guidelines state that metformin is absolutely contraindicated in patients with eGFR <30 mL/min/1.73 m² and should not be used 5, 1
• For patients with eGFR 30-44 mL/min/1.73 m² at restart, the Kidney International guidelines recommend reducing the metformin dose to half the maximum (typically 500-1000 mg daily) 5

Alternative Therapies

• The Kidney International guidelines suggest considering alternative glucose-lowering agents such as GLP-1 receptor agonists, DPP-4 inhibitors, or insulin in patients with eGFR <30 mL/min/1.73 m² 5

Timing of Metformin Restart

• The European Journal of Nuclear Medicine and Molecular Imaging recommends withholding metformin for 48 hours post-procedure in patients who had it discontinued and restarting only after confirming renal function remains stable at 48 hours 3, 4